绥美凯使用说明

It is a compound preparation. Each tablet contains 50 mg of dolutegravir sodium (calculated as dolutegravir), 600 mg of abacavir sulfate (calculated as abacavir) and 300 mg of lamivudine. It is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). Among them, dolutegravir can inhibit HIV integrase by binding to the active site of integrase and blocking the strand transfer step of reverse transcription deoxyribonucleic acid (DNA) integration (a key step in the HIV replication cycle).

This product should be taken under the guidance of a physician with experience in HIV infection. Dosage Adults and Adolescents (Weighing at least 40 kg) For adults and adolescents, the recommended dose is one tablet once daily. Adults or adolescents whose body weight is less than 40 kg should not be given this product because this product is a fixed-dose tablet and the dose cannot be reduced. This product is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines. Missed dose If the patient misses a dose of this product and there are more than 4 hours before the next dose, the patient should take this product as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule. Geriatric Patients There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients aged ≥65 years, and there is no evidence that older patients require different doses than younger adult patients. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when administering the drug in this age group. Patients with renal impairment and creatinine clearance less than 50mL/min are not recommended to take this product. Hepatic Impairment Abacavir is primarily metabolized by the liver. There are no clinical data in patients with moderate or severe hepatic impairment; therefore, use of this product is not recommended unless deemed necessary. For patients with mild hepatic impairment (Child-Pugh score 5-6), close monitoring is required, including monitoring abacavir plasma levels if feasible. Pediatric Population The safety and effectiveness of this product in children under 12 years of age have not been established. No data yet. Dosage: Oral administration: This product can be taken with or without food.

It is recommended that everyone learn more about the methods of preventing AIDS to reduce the incidence of AIDS. When AIDS occurs, do not be overly pessimistic and world-weary. This is also detrimental to the condition. The correct use of some antiviral drugs () can help people prolong their survival.